Mankind Pharma Limited
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Healthy return on equity of 19.3%
Concerns1
- Negative free cash flow (βΉ11 Cr)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 8 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ9.50 K Cr | β | βΉ1.95 K Cr | β | β | 13.3% | 10.1% | 3.7% |
| Mar 2024 | βΉ8.63 K Cr | β | βΉ1.88 K Cr | β | β | 19.3% | 6.2% | 50.3% |
| Mar 2023 | βΉ8.13 K Cr | β | βΉ1.25 K Cr | β | β | 16.0% | 8.6% | -10.2% |
| Mar 2022 | βΉ7.49 K Cr | β | βΉ1.39 K Cr | β | β | 21.2% | 35.4% | 28.1% |
| Mar 2021 | βΉ5.53 K Cr | β | βΉ1.08 K Cr | β | β | 22.9% | 15.4% | 13.2% |
| Mar 2020 | βΉ4.79 K Cr | β | βΉ958.00 Cr | β | β | 26.2% | 25.2% | 86.4% |
| Mar 2019 | βΉ3.83 K Cr | β | βΉ514.00 Cr | β | β | 16.8% | -2.3% | -25.9% |
| Mar 2018 | βΉ3.92 K Cr | β | βΉ694.00 Cr | β | β | 23.2% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 9,691 |
| Total Expenses | 7,102 |
| EBIT / Operating Profit | 2,589 |
| OPM % | 27% |
| Other Income | 432 |
| Finance Costs | 656 |
| Depreciation & Amortisation | 392 |
| Profit Before Tax | 1,972 |
| Tax % | - |
| Net Profit / PAT | 1,666 |
| EPS (βΉ) | 40.38 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Mankind Pharma Limitedthis co. | βΉ91.28 K Cr | βΉ9.50 K Cr | 54.80 | 5.89 | 34.31 | 10.1% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |